Search Results

You are looking at 1 - 4 of 4 items for :

  • "Novoseven" x
  • Refine by Access: All Content x
Clear All

Tapasztalataink a rekombináns faktor VIIa-val (NovoSeven®) a magas kockázatú szívműtétek vérzéses szövődményeinek kezelésében

Our experience with recombinant activated factor VII (NovoSeven®) in the high risk cardiosurgical patients with bleeding complication

Magyar Sebészet
Authors:
Szabolcs Miskolczi
,
Miklós Vaszily
,
Csaba Papp
, and
Árpád Péterffy

GF Gensisn C Sorbara 2006 Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery Anaesth Analg

Restricted access

–159. 4 Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109

Restricted access

Arkin, S., Cooper, H. A., Hutter, J. J. és mtsa: Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitor. Results of the Novoseven emergency-use-program. Haemophilia, 1998

Restricted access

A szerzett haemophilia A sikeres kezelése

Successful treatment of acquired haemophilia A

Orvosi Hetilap
Authors:
Andrea Kovács
,
Balázs Tajti
,
István Szoboszlay
,
Zsuzsanna Bereczky
, and
Péter Ilonczai

–46. 21 Hedner U. Recombinant factor VIIa (NovoSeven ® ) as a hemostatic agent. In: Wiestner A, Young NS. (eds.) Seminars in Hematology. W.B. Saunders, Philadelphia, PA, 2001; pp. 43

Restricted access